KYMR Kymera Therapeutics
- 37.400
- +1.100+3.03%
- 37.860
- +0.460+1.23%
Kymera Therapeutics News
Kymera Therapeutics | 10-Q: Quarterly report
Kymera Therapeutics | 8-K: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics | ARS: Annual Report to Security Holders
Kymera Therapeutics | DEFA14A: Others
Kymera Therapeutics | DEF 14A: Definitive information statements
Kymera Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Baker Bros. Advisors LP(9.8%),Baker Bros. Advisors (GP) LLC(9.8%), etc.
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
Kymera Therapeutics | 3: Initial statement of beneficial ownership of securities-Director BAKER BROS. ADVISORS LP
Kymera Therapeutics | 8-K: Current report
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Booth Bruce
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Atlas Venture Fund X, L.P.
Kymera Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Booth Bruce
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Kymera Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Analysis
Price Target
No Data
